Ad hoc:Q-Cells SE:Ad hoc: ABO placement completed successfully - subscription price for rights issue set at 2.16 Euro per new share

Q-Cells SE /  / Ad hoc: ABO placement completed successfully - subscription price for rights issue set at 2.16 Euro per new share processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement. 
 
Bitterfeld-Wolfen,   28 September  2010 -  The  Board  of  Q-Cells  SE  has  now
determined  the key terms  of the rights  issue. The subscription  price for the
58.765.955 new bearer shares is set at 2.16 Euro per share.
 
Prior  to  this  decision  9.9 million  new  ex  rights  bearer  shares based on
subscription  rights  held  by  Good  Energies  (Solar  Investments)  S.à  r.l.,
Luxemburg,  had been  placed by  way of  an Accelerated Bookbuilt Offering (ABO)
with institutional investors without subscription rights at a price of 3.60 Euro
per  share. The  subscription price  for new  shares is  40% lower than  the ABO
price.  The subscription  period for  new shares,  which will commence tomorrow,
will  run until the end of 12 October  2010. Net proceeds to Q-Cells SE from the
rights  issue  pursuant  to  the  offer  conditions  as  stated  will  amount to
approximately up to 120 million Euro if all bearer shares can be placed.
 
It  is envisaged that the shares placed under the Accelerated Bookbuilt Offering
will be included in the existing trading in the Prime Standard market segment of
the  Frankfurt Stock Exchange by 1 October  2010, and delivery and settlement of
these  shares under the  Accelerated Bookbuilt Offering  will occur on 4 October
2010. Delivery  and settlement of the new shares pursuant to the rights issue is
envisaged  for 14 October 2010. At this  time it is also  planned to include the
new  shares in  trading in  the Prime  Standard market  segment of the Frankfurt
Stock Exchange.
 
The  subscription period for  the new convertible  bond and the repurchase offer
for the outstanding convertible bond 2007/2012 will commence at the same time as
the subscription period for the rights issue.
 
Contact information:
Q-Cells SE
OT Thalheim
Sonnenallee 17 - 21
06766 Bitterfeld-Wolfen, Germany
www.q-cells.com
 
Investor Relations:
Stefan Lissner
Phone: +49 (0)3494 - 6699 10101
investor@q-cells.com
 
Corporate Communications:
Ina von Spies
Phone: +49 (0)3494 - 6699 10121
presse@q-cells.com
 
Disclaimer
This  communication is  only being  distributed to  and is  only directed at (i)
persons  who are outside the United  Kingdom or (ii) to investment professionals
falling  within Article  19(5) of the  Financial Services  and Markets Act 2000
(Financial   Promotion)  Order  2005 (the  "Order")  or  (iii)  high  net  worth
companies,  and other persons  to whom it  may lawfully be communicated, falling
within  Article 49(2)(a) to  (d) of  the Order  (all such persons together being
referred  to as "relevant  persons"). The securities  are only available to, and
any  invitation,  offer  or  agreement  to  subscribe for, purchase or otherwise
acquire  such securities  will be  engaged in  only with,  relevant persons. Any
person  who is not a relevant person should  not act or rely on this document or
any of its contents.
 
Stabilisation/Regulation (EC) 2273/2003 and FSA.
This  document  is  an  advertisement  for  the  purposes of applicable measures
implementing  Directive 2003/71/EC (such Directive, together with any applicable
implementing  measures in the  relevant home Member  State under such Directive,
the  "Prospectus Directive"). A  prospectus prepared pursuant  to the Prospectus
Directive  is expected to be  published on 28 September 2010, following approval
by  the German  Federal Financial  Supervisory Authority,  the prospectus can be
obtained    from    Q-Cells   SE,   OT   Thalheim,   Sonnenallee   17-21, 06766
Bitterfeld-Wolfen, Germany.
 
In  any  EEA  Member  State  other  than  Germany that has implemented Directive
2003/71/EC (together  with any  applicable implementing  measures in  any Member
State,  the "Prospectus Directive") this communication  is only addressed to and
directed  at qualified investors in that Member  State within the meaning of the
Prospectus Directive.
 
This notification does not constitute a prospectus. Only the prospectus contains
the  information for investors required pursuant  to the legal requirements. The
German  version  of  the  prospectus  was  published on 28 September 2010 and is
available  free of charge on  the website of Q-Cells  SE (www.q-cells.de) and on
request  in printed form from Q-Cells SE, OT Thalheim, Sonnenallee 17-21, 06766
Bitterfeld-Wolfen.
 
[HUG#1447316]
 
--- End of Message --- 
 
Q-Cells SE
 OT Thalheim, Sonnenallee 17-21  Bitterfeld-Wolfen Germany
 
WKN: 555866;ISIN: DE0005558662;Index:TecDAX,Prime All Share,CDAX,GEX;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;
 
This announcement is distributed by Thomson Reuters on behalf of 
Thomson Reuters clients. The owner of this announcement warrants that: 
(i) the releases contained herein are protected by copyright and 
    other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and 
     originality of the information contained therein. 
 
Source: Q-Cells SE via Thomson Reuters ONE